Aminoglycosides. Redesign strategies for improved antibiotics and compounds for treatment of human genetic diseases

Methods in Enzymology

Volumn 478, Issue C, 2010, Pages 437-462

  Pokrovskaya, Varvara ^a   Nudelman, Igor ^a   Kandasamy, Jeyakumar ^a   Baasov, Timor ^a  

^a TECHNION ISRAEL INSTITUTE OF TECHNOLOGY   (Israel)

Author keywords

[No Author keywords available]

Indexed keywords

AMINOGLYCOSIDE ANTIBIOTIC AGENT; CARBOHYDRATE DERIVATIVE; CIPROFLOXACIN; DIBEKACIN; FRAMYCETIN; GENTAMICIN; GENTAMICIN C; HABEKACIN; KANAMYCIN B; NB 45; PAROMOMYCIN; TOBRAMYCIN; UNCLASSIFIED DRUG;

ANIMAL CELL; ANIMAL EXPERIMENT; ANTIBACTERIAL ACTIVITY; ANTIBIOTIC RESISTANCE; BACILLUS ANTHRACIS; BACTERIAL STRAIN; BOOK; CYTOTOXICITY; DRUG ACTIVITY; DRUG BINDING; DRUG DESIGN; DRUG EFFECT; DRUG SAFETY; DRUG STRUCTURE; GENETIC DISORDER; LD 50; MOUSE; NONHUMAN; PRIORITY JOURNAL;

BACTERIA (MICROORGANISMS); MAMMALIA;

EID: 77956279830     PISSN: 00766879     EISSN: None     Source Type: Book Series    
DOI: 10.1016/S0076-6879(10)78021-6     Document Type: Chapter

References (67)

1. Albiero L., Bamonte F., Ongini E., Parravicini L. Comparison of neuromuscular effects and acute toxicity of some aminoglycoside antibiotics. Arch. Int. Pharmacodyn. Thér. 1978, 233:343-350.
2. Aminoglycoside Antibiotics: From Chemical Biology to Drug Discovery 2007, Wiley, Hoboken, New Jersey. D.P. Arya (Ed.).
3. Barbachyn M.R. Recent advances in the discovery of hybrid antibacterial agents. Annu. Rep. Med. Chem. 2008, 43:281-290.
4. Bottger E.C., Springer B., Prammananan T., Kidan Y., Sander P. Structural basis for selectivity and toxicity of ribosomal antibiotics. EMBO Rep. 2001, 2:318-323.
5. Bremner J.B., Ambrus J.I., Samosorn S. Dual action-based approaches to antibacterial agents. Curr. Med. Chem. 2007, 14:1459-1477.
6. Carter A.P., Clemons W.M., Brodersen D.E., Morgan-Warren R.J., Wimberly B.T., Ramakrishnan V. Functional insights from the structure of the 30S ribosomal subunit and its interactions with antibiotics. Nature 2000, 407:340-348.
7. Chait R., Craney A., Kishony R. Antibiotic interactions that select against resistance. Nature 2007, 446:668-671.
8. Chen L., Hainrichson M., Bourdetsky D., Mor A., Yaron S., Baasov T. Structure-toxicity relationship of aminoglycosides: Correlation of 2'-amine basicity with acute toxicity in pseudo-disaccharide scaffolds. Bioorg. Med. Chem. 2008, 16:8940-8951.
9. Chittapragada M., Roberts S., Ham Y.W. Aminoglycosides: Molecular insights on the recognition of RNA and aminoglycoside mimics. Perspect. Med. Chem. 2009, 3:21-37.
10. Davis M.A., Baker K.N., Orfe L.H., Shah D., Besser T.E., Call D.R. Discovery of a gene conferring multiple aminoglycoside resistance in Escherichia coli. Antimicrob. Agents Chemother. 2010, 54(6):2666-2669.
11. Eustice D.C., Wilhelm J.M. Fidelity of the eukaryotic codon-anticodon interaction: Interference by aminoglycoside antibiotics. Biochemistry 1984, 23:1462-1467.
12. Forge A., Schacht J. Aminoglycoside antibiotics. Audiol. Neurootol. 2000, 5:3-22.
13. Forino M., Johnson S., Wong T.Y., Rozanov D.V., Savinov A.Y., Li W., Fattorusso R., Becattini B., Orry A.J., Jung D., Abagyan R.A., Smith J.W., et al. Efficient synthetic inhibitors of anthrax lethal factor. Proc. Natl. Acad. Sci. USA 2005, 102:9499-9504.
14. Fourmy D., Yoshizawa S., Puglisi J.D. Paromomycin binding induces a local conformational change in the A-site of 16 S rRNA. J. Mol. Biol. 1998, 277:333-345.
15. Francois B., Russell R.J., Murray J.B., Aboul-ela F., Masquida B., Vicens Q., Westhof E. Crystal structures of complexes between aminoglycosides and decoding A site oligonucleotides: Role of the number of rings and positive charges in the specific binding leading to miscoding. Nucleic Acids Res. 2005, 33:5677-5690.
16. Fridman M., Belakhov V., Yaron S., Baasov T. A new class of branched aminoglycosides: Pseudo-pentasaccharide derivatives of neomycin B. Org. Lett. 2003, 5:3575-3578.
17. Fridman M., Belakhov V., Lee L.V., Liang F.S., Wong C.H., Baasov T. Dual effect of synthetic aminoglycosides: Antibacterial activity against Bacillus anthracis and inhibition of anthrax lethal factor. Angew. Chem. Int. Ed. Engl. 2005, 44:447-452.
18. Guthrie O.W. Aminoglycoside induced ototoxicity. Toxicology 2008, 249:91-96.
19. Hainrichson M., Pokrovskaya V., Shallom-Shezifi D., Fridman M., Belakhov V., Shachar D., Yaron S., Baasov T. Branched aminoglycosides: Biochemical studies and antibacterial activity of neomycin B derivatives. Bioorg. Med. Chem. 2005, 13:5797-5807.
20. Hainrichson M., Yaniv O., Cherniavsky M., Nudelman I., Shallom-Shezifi D., Yaron S., Baasov T. Overexpression and initial characterization of the chromosomal aminoglycoside 3'-O-phosphotransferase APH(3')-IIb from Pseudomonas aeruginosa. Antimicrob. Agents Chemother. 2007, 51:774-776.
21. Hainrichson M., Nudelman I., Baasov T. Designer aminoglycosides: The race to develop improved antibiotics and compounds for the treatment of human genetic diseases. Org. Biomol. Chem. 2008, 6:227-239.
22. Hermann T. Aminoglycoside antibiotics: Old drugs and new therapeutic approaches. Cell. Mol. Life Sci. 2007, 64:1841-1852.
23. Hobbie S.N., Akshay S., Kalapala S.K., Bruell C.M., Shcherbakov D., Bottger E.C. Genetic analysis of interactions with eukaryotic rRNA identify the mitoribosome as target in aminoglycoside ototoxicity. Proc. Natl. Acad. Sci. USA 2008, 105:20888-20893.
24. Hobbie S.N., Bruell C.M., Akshay S., Kalapala S.K., Shcherbakov D., Bottger E.C. Mitochondrial deafness alleles confer misreading of the genetic code. Proc. Natl. Acad. Sci. USA 2008, 105:3244-3249.
25. Howard M.T., Shirts B.H., Petros L.M., Flanigan K.M., Gesteland R.F., Atkins J.F. Sequence specificity of aminoglycoside-induced stop condon readthrough: Potential implications for treatment of Duchenne muscular dystrophy. Ann. Neurol. 2000, 48:164-169.
26. Howard M.T., Anderson C.B., Fass U., Khatri S., Gesteland R.F., Atkins J.F., Flanigan K.M. Readthrough of dystrophin stop codon mutations induced by aminoglycosides. Ann. Neurol. 2004, 55:422-426.
27. Ishino K., Ishikawa J., Ikeda Y., Hotta K. Characterization of a bifunctional aminoglycoside-modifying enzyme with novel substrate specificity and its gene from a clinical isolate of methicillin-resistant Staphylococcus aureus with high arbekacin resistance. J. Antibiot. 2004, 57:679-686.
28. Jana S., Deb J.K. Molecular understanding of aminoglycoside action and resistance. Appl. Microbiol. Biotechnol. 2006, 70:140-150.
29. Kaul M., Barbieri C.M., Pilch D.S. Aminoglycoside-induced reduction in nucleotide mobility at the ribosomal RNA A-site as a potentially key determinant of antibacterial activity. J. Am. Chem. Soc. 2006, 128:1261-1271.
30. Kellermayer R., Szigeti R., Keeling K.M., Bedekovics T., Bedwell D.M. Aminoglycosides as potential pharmacogenetic agents in the treatment of Hailey-Hailey disease. J. Invest. Dermatol. 2006, 126:229-231.
31. Kondo S., Hotta K. Semisynthetic aminoglycoside antibiotics: Development and enzymatic modifications. J. Infect. Chemother. 1999, 5:1-9.
32. Kondo J., Hainrichson M., Nudelman I., Shallom-Shezifi D., Barbieri C.M., Pilch D.S., Westhof E., Baasov T. Differential selectivity of natural and synthetic aminoglycosides towards the eukaryotic and prokaryotic decoding A sites. Chembiochem 2007, 8:1700-1709.
33. Kurtz D.I. Fidelity of protein synthesis with chicken embryo mitochondrial and cytoplasmic ribosomes. Biochemistry 1974, 13:572-577.
34. Li J., Chang C.W. Recent developments in the synthesis of novel aminoglycoside antibiotics. Anti-infective Agents Med. Chem. 2006, 5:255-271.
35. Llewellyn N.M., Spencer J.B. Biosynthesis of 2-deoxystreptamine-containing aminoglycoside antibiotics. Nat. Prod. Rep. 2006, 23:864-874.
36. Llewellyn N.M., Spencer J.B. Chemoenzymatic acylation of aminoglycoside antibiotics. Chem. Commun. 2008, (32):3786-3788.
37. Long D.D., Marquess D.G. Novel heterodimer antibiotics: A review of recent patent literature. Future Med. Chem. 2009, 1(6):1037-1050.
38. Magnet S., Blanchard J.S. Molecular insights into aminoglycoside action and resistance. Chem. Rev. 2005, 105:477-498.
39. Manuvakhova M., Keeling K., Bedwell D.M. Aminoglycoside antibiotics mediate context-dependent suppression of termination codons in a mammalian translation system. RNA 2000, 6:1044-1055.
40. McKee E.E., Ferguson M., Bentley A.T., Marks T.A. Inhibition of mammalian mitochondrial protein synthesis by oxazolidinones. Antimicrob. Agents Chemother. 2006, 50:2042-2049.
41. Moazed D., Noller H.F. Interaction of antibiotics with functional sites in 16S ribosomal RNA. Nature 1987, 327:389-394.
42. Nagai J., Takano M. Molecular aspects of renal handling of aminoglycosides and strategies for preventing the nephrotoxicity. Drug Metab. Pharmacokinet. 2004, 19:159-170.
43. Nudelman I., Rebibo-Sabbah A., Shallom-Shezifi D., Hainrichson M., Stahl I., Ben-Yosef T., Baasov T. Redesign of aminoglycosides for treatment of human genetic diseases caused by premature stop mutations. Bioorg. Med. Chem. Lett. 2006, 16:6310-6315.
44. Nudelman I., Chen L., Llewellyn N.M., Sahraoui E.H., Cherniavsky M., Spencer J.B., Baasov T. Combined chemical-enzymatic assembly of aminoglycoside derivatives with N-1-AHB side chain. Adv. Synth. Catal. 2008, 350:1682-1688.
45. Nudelman I., Rebibo-Sabbah A., Cherniavsky M., Belakhov V., Hainrichson M., Chen F., Schacht J., Pilch D.S., Ben-Yosef T., Baasov T. Development of novel aminoglycoside (NB54) with reduced toxicity and enhanced suppression of disease-causing premature stop mutations. J. Med. Chem. 2009, 52:2836-2845.
46. Nudelman I., Glikin D., Smolkin B., Hainrichson M., Belakhov V., Baasov T. Repairing faulty genes by aminoglycosides: Development of new derivatives of geneticin (G418) with enhanced suppression of diseases-causing nonsense mutations. Bioorg. Med. Chem. 2010, 18(11):3735-3746.
47. Numa M.M., Lee L.V., Hsu C.C., Bower K.E., Wong C.H. Identification of novel anthrax lethal factor inhibitors generated by combinatorial Pictet-Spengler reaction followed by screening in situ. Chembiochem 2005, 6:1002-1006.
48. Ogle J.M., Ramakrishnan V. Structural insights into translational fidelity. Annu. Rev. Biochem. 2005, 74:129-177.
49. Palmer A.C., Angelino E., Kishony R. Chemical decay of an antibiotic inverts selection for resistance. Nat. Chem. Biol. 2010, 6:105-107.
50. Pokrovskaya V., Belakhov V., Hainrichson M., Yaron S., Baasov T. Design, synthesis, and evaluation of novel fluoroquinolone-aminoglycoside hybrid antibiotics. J. Med. Chem. 2009, 52:2243-2254.
51. Rebibo-Sabbah A., Nudelman I., Ahmed Z.M., Baasov T., Ben-Yosef T. In vitro and ex vivo suppression by aminoglycosides of PCDH15 nonsense mutations underlying type 1 Usher syndrome. Hum. Genet. 2007, 122:373-381.
52. Schatz A., Bugie E., Waksman S.A. Streptomycin, a substance exhibiting antibiotic activity against gram-positive and gram-negative bacteria. Proc. Soc. Exp. Biol. Med. 1944, 55:66-69.
53. Selmer M., Dunham C.M., Murphy F.V., Weixlbaumer A., Petry S., Kelley A.C., Weir J.R., Ramakrishnan V. Structure of the 70S ribosome complexed with mRNA and tRNA. Science 2006, 313:1935-1942.
54. Shitara T., Umemura E., Tsuchiya T., Matsuno T. Synthesis of 5-deoxy-5-epifluoro derivatives of arbekacin, amikacin, and 1-N-[(S)-4-amino-2-hydroxybutanoyl]tobramycin (study on structure-toxicity relationships). Carbohydr. Res. 1995, 276:75-89.
55. Shoop W.L., Xiong Y., Wiltsie J., Woods A., Guo J., Pivnichny J.V., Felcetto T., Michael B.F., Bansal A., Cummings R.T., Cunningham B.R., Friedlander A.M., et al. Anthrax lethal factor inhibition. Proc. Natl. Acad. Sci. USA 2005, 102:7958-7963.
56. Silva J.G., Carvalho I. New insights into aminoglycoside antibiotics and derivatives. Curr. Med. Chem. 2007, 14:1101-1119.
57. Sundar S., Chakravarty J. Paromomycin in the treatment of leishmaniasis. Expet. Opin. Investig. Drugs 2008, 17:787-794.
58. Talaska A.E., Schacht J. Adverse effects of aminoglycoside therapy. Aminoglycoside antibiotics: from chemical biology to drug discovery 2007, 255-266. Wiley, Hoboken, New Jersey. D.P. Arya (Ed.).
59. Aminoglycoside Antibiotics 1982, Springer, New York, Heidelberg. H. Umezawa, I.R. Hooper (Eds.).
60. Vakulenko S.B., Mobashery S. Versatility of aminoglycosides and prospects for their future. Clin. Microbiol. Rev. 2003, 16:430-450.
61. Vicens Q., Westhof E. Molecular recognition of aminoglycoside antibiotics by ribosomal RNA and resistance enzymes: An analysis of x-ray crystal structures. Biopolymers 2003, 70:42-57.
62. Wang J., Chang C.W.T. Design, chemical synthesis, and antibacterial activity of kanamycin and neomycin class aminoglycoside antibiotics. Aminoglycoside Antibiotics: From Chemical Biology to Drug Discovery 2007, 141-180. Wiley, Hoboken, New Jersey. 2nd edn. D.P. Arya (Ed.).
63. Wright G.D. Mechanisms of aminoglycoside antibiotic resistance. Bacterial Resistance to Antimicrobials 2008, 71-101. CRC press, Taylor & Francis group, Boca Raton, FL. 2nd edn. K. Lewis, A.A. Salyers, H.W. Taber, R.G. Wax (Eds.).
64. Yeh P.J., Hegreness M.J., Aiden A.P., Kishony R. Drug interactions and the evolution of antibiotic resistance. Nat. Rev. 2009, 7:460-466.
65. Zhang W.L., Fisher J.F., Mobashery S. The bifunctional enzymes of antibiotic resistance. Curr. Opin. Microbiol. 2009, 12:505-511.
66. Zhou J., Wang G., Zhang L.H., Ye X.S. Modifications of aminoglycoside antibiotics targeting RNA. Med. Res. Rev. 2007, 27:279-316.
67. Zingman L.V., Park S., Olson T.M., Alekseev A.E., Terzic A. Aminoglycoside-induced translational read-through in disease: Overcoming nonsense mutations by pharmacogenetic therapy. Clin. Pharmacol. Ther. 2007, 81:99-103.